QI
PDLI

QS Investors’s PDL BioPharma, Inc. PDLI Stock Holding History

QS Investors’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,124
Closed -$4K – 1670
2020
Q2 		$4K Hold
1,124
– – ﹤0.01% 1630
2020
Q1 		$4K Hold
1,124
– – ﹤0.01% 1632
2019
Q4 		$4K Sell
1,124
-135,206
-99% -$393K ﹤0.01% 1606
2019
Q3 		$295K Hold
136,330
– – ﹤0.01% 1101
2019
Q2 		$429K Hold
136,330
– – ﹤0.01% 1017
2019
Q1 		$508K Hold
136,330
– – 0.01% 967
2018
Q4 		$396K Hold
136,330
– – 0.01% 962
2018
Q3 		$359K Hold
136,330
– – ﹤0.01% 1045
2018
Q2 		$319K Buy
136,330
+11,290
+9% +$31.5K ﹤0.01% 1059
2018
Q1 		$368K Buy
125,040
+115,736
+1,244% +$316K ﹤0.01% 1013
2017
Q4 		$25K Buy
9,304
+3,229
+53% +$9.92K ﹤0.01% 1528
2017
Q3 		$21K Hold
6,075
– – ﹤0.01% 1573
2017
Q2 		$15K Hold
6,075
– – ﹤0.01% 1586
2017
Q1 		$14K Sell
6,075
-42,566
-88% -$94.2K ﹤0.01% 1624
2016
Q4 		$103K Sell
48,641
-769,895
-94% -$2.15M ﹤0.01% 1276
2016
Q3 		$2.74M Sell
818,536
-403,715
-33% -$1.28M 0.02% 571
2016
Q2 		$3.84M Buy
1,222,251
+219,997
+22% +$734K 0.03% 471
2016
Q1 		$3.34M Buy
1,002,254
+994,051
+12,118% +$3.1M 0.03% 510
2015
Q4 		$29K Sell
8,203
-350,580
-98% -$1.47M ﹤0.01% 1392
2015
Q3 		$1.8M Buy
358,783
+355,200
+9,913% +$2.04M 0.02% 648
2015
Q2 		$23K Sell
3,583
-432,900
-99% -$2.9M ﹤0.01% 1340
2015
Q1 		$3.07M Sell
436,483
-147,301
-25% -$1.07M 0.03% 505
2014
Q4 		$4.5M Sell
583,784
-2,222,616
-79% -$17.6M 0.05% 392
2014
Q3 		$21M Buy
2,806,400
+1,479,500
+112% +$13.7M 0.56% 44
2014
Q2 		$12.8M Buy
1,326,900
+1,011,900
+321% +$9.02M 0.34% 80
2014
Q1 		$2.62M Sell
315,000
-579,100
-65% -$4.96M 0.08% 216
2013
Q4 		$7.55M Buy
894,100
+240,700
+37% +$2.03M 0.29% 94
2013
Q3 		$5.21M Sell
653,400
-238,200
-27% -$1.91M 0.22% 122
2013
Q2 		$6.88M Buy
+891,600
New +$6.95M 0.24% 124

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SPC
Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

QS Investors's PDLI Position: Q3 2020 in Review

QS Investors sold out of PDL BioPharma, Inc. (PDLI) in Q3 2020, closing a stake of 1,124 shares — an estimated $4K sold.

QS Investors first reported a position in PDLI in Q2 2013 and held it in 29 quarters. The position peaked at $21M in Q3 2014. 132 funds tracked by Wall St. Rank hold PDLI as of Q3 2020.

  • QS Investors reported no remaining PDL BioPharma, Inc. position as of Q3 2020 after selling out during the quarter.
  • QS Investors sold 1,124 PDL BioPharma, Inc. shares in Q3 2020, an estimated $4K.
  • QS Investors first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 29 quarters.
  • QS Investors's PDL BioPharma, Inc. position peaked at $21M in Q3 2014.
  • 132 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2020.

Based on QS Investors's 13F filing for Q3 2020, filed 12 Nov 2020.